CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 41 enrolled
Drug / intervention
Caffeine (200mg) +1 moredietary
Likely dose
Caffeine (200mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02940808
NCT02940808N/ACompleted

The Effects of a Single Administration of a Moderate Dose of Caffeine on Cognitive Control and Spontaneous EEG Theta/Beta Ratio

Leiden University Medical Center·interventional·Posted Oct 21, 2016·Updated Mar 8, 2017

In Brief

A clinical study evaluating Caffeine (200mg) and Placebo for Caffeine. Completed, enrolled 41 participants across 1 site.

Detailed Summary

Cognitive control driven by the prefrontal cortex (PFC) of the brain is thought to be important for goal-directed control over stimulus-driven processes. EEG-measured spontaneous theta/beta ratio (TBR) may potentially be used as an electrophysiological marker for this PFC-mediated cognitive control. In the present study the investigators further examine TBR as an electrophysiological marker for cognitive control, by administering caffeine to forty healthy female participants. After a first training session, participants will visit the lab twice in separate weeks, during which they will orally consume one capsule containing 200mg of caffeine, and one capsule containing a placebo substance (double-blind and random order of administration). EEG will be measured before and after capsule consumption, and cognitive control tasks will be administered after capsule consumption. Generally, the investigators expect that caffeine will decrease TBR and thereby increase cognitive control. Additionally, the investigators expect that individual differences in baseline frontal (reflected by TBR) and central dopaminergic (reflected by spontaneously-measured eye-blink rates; EBR) activity will moderate the relationship between caffeine and cognitive control. Furthermore, the effects of caffeine on specifically hypervigilance for threatening distractors (taking into account a possible moderating role of trait anxiety) were examined as a separate research question.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCaffeine
CountriesNetherlands
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedOct 21, 2016
Enrollment StartMay 1, 2016
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.7 years ago

Interventions

Caffeine (200mg)dietary

Oral consumption of capsule containing 200mg caffeine.

Placeboother

Oral consumption of capsule containing a placebo substance.